The fair competition protocol of medical drug transaction is the ground for value decisions that are reflected from opinions of stakeholders and governmental agencies in the pharmecuetical industry. (the 3rd revision: reviewed by fair trade commission, office for monitoring manufacturers – 601,2010,10.17)

It aims at discouraging firms to induce customers inappropriately according to the 23rd article 1st section 3rd item of fair trade act concerning monopoly regulation and fair trade, ensuring that competitors build fair competition rules in the distribution of medical products, and improving the health conditions of people.